Literature DB >> 15803365

Pathology of breast cancer in women with constitutional CHEK2 mutations.

Tomasz Huzarski1, Cezary Cybulski, Wenancjusz Domagała, Jacek Gronwald, Tomasz Byrski, Marek Szwiec, Stanisław Woyke, Steven A Narod, Jan Lubiński.   

Abstract

The power of association studies between polymorphic genetic variants and breast cancer may be enhanced if the cancer subjects are subclassified by histologic subgroup. In this study we classified 482 unselected breast cancers from Szczecin, Poland by histology (ductal, lobular, medullary, other). All women were genotyped for three founder mutations in the CHEK2 gene (1100delC, IVS2 + 1G > A and I157T). There was no significant overall association between CHEK2 and breast cancer (OR = 1.3; p = 0.30), but among those with lobular carcinoma the association with the I157T missense mutation was very strong (OR = 6.6; p > 0.0001). This is the first report to demonstrate that different mutations of the same gene may be associated with specific histologic subtypes of cancer.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15803365     DOI: 10.1007/s10549-004-3778-2

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  11 in total

Review 1.  Genotype/Phenotype correlations in patients with hereditary breast cancer.

Authors:  Maike Wittersheim; Reinhard Büttner; Birgid Markiefka
Journal:  Breast Care (Basel)       Date:  2015-02       Impact factor: 2.860

2.  Emerging Concepts in Breast Cancer Risk Prediction.

Authors:  Gretchen L Gierach; Xiaohong R Yang; Jonine D Figueroa; Mark E Sherman
Journal:  Curr Obstet Gynecol Rep       Date:  2013-03

3.  Germline Pathogenic Variants in Cancer Predisposition Genes Among Women With Invasive Lobular Carcinoma of the Breast.

Authors:  Siddhartha Yadav; Chunling Hu; Katherine L Nathanson; Jeffrey N Weitzel; David E Goldgar; Peter Kraft; Rohan D Gnanaolivu; Jie Na; Hongyan Huang; Nicholas J Boddicker; Nicole Larson; Chi Gao; Song Yao; Clarice Weinberg; Celine M Vachon; Amy Trentham-Dietz; Jack A Taylor; Dale R Sandler; Alpa Patel; Julie R Palmer; Janet E Olson; Susan Neuhausen; Elena Martinez; Sara Lindstrom; James V Lacey; Allison W Kurian; Esther M John; Christopher Haiman; Leslie Bernstein; Paul W Auer; Hoda Anton-Culver; Christine B Ambrosone; Rachid Karam; Elizabeth Chao; Amal Yussuf; Tina Pesaran; Jill S Dolinsky; Steven N Hart; Holly LaDuca; Eric C Polley; Susan M Domchek; Fergus J Couch
Journal:  J Clin Oncol       Date:  2021-10-21       Impact factor: 44.544

4.  Hereditary breast and ovarian cancer.

Authors:  Jacek Gronwald; Tomasz Byrski; Tomasz Huzarski; Oleg Oszurek; Anna Janicka; Jolanta Szymanska-Pasternak; Bohdan Górski; Janusz Menkiszak; Izabella Rzepka-Górska; Jan Lubinski
Journal:  Hered Cancer Clin Pract       Date:  2008-06-15       Impact factor: 2.857

5.  Constitutional CHEK2 mutations are infrequent in early-onset and familial breast/ovarian cancer patients from Pakistan.

Authors:  Muhammad U Rashid; Noor Muhammad; Saima Faisal; Asim Amin; Ute Hamann
Journal:  BMC Cancer       Date:  2013-06-27       Impact factor: 4.430

Review 6.  Pathology of hereditary breast cancer.

Authors:  Petra van der Groep; Elsken van der Wall; Paul J van Diest
Journal:  Cell Oncol (Dordr)       Date:  2011-02-19       Impact factor: 6.730

7.  Linkage disequilibrium mapping of CHEK2: common variation and breast cancer risk.

Authors:  Kristjana Einarsdóttir; Keith Humphreys; Carine Bonnard; Juni Palmgren; Mark M Iles; Arvid Sjölander; Yuqing Li; Kee Seng Chia; Edison T Liu; Per Hall; Jianjun Liu; Sara Wedrén
Journal:  PLoS Med       Date:  2006-05-09       Impact factor: 11.069

Review 8.  CHEK2 Germline Variants in Cancer Predisposition: Stalemate Rather than Checkmate.

Authors:  Lenka Stolarova; Petra Kleiblova; Marketa Janatova; Jana Soukupova; Petra Zemankova; Libor Macurek; Zdenek Kleibl
Journal:  Cells       Date:  2020-12-12       Impact factor: 6.600

9.  Risk for contralateral breast cancer among carriers of the CHEK2*1100delC mutation in the WECARE Study.

Authors:  L Mellemkjaer; C Dahl; J H Olsen; L Bertelsen; P Guldberg; J Christensen; A-L Børresen-Dale; M Stovall; B Langholz; L Bernstein; C F Lynch; K E Malone; R W Haile; M Andersson; D C Thomas; P Concannon; M Capanu; J D Boice; J L Bernstein
Journal:  Br J Cancer       Date:  2008-02-05       Impact factor: 7.640

10.  Patient survival and tumor characteristics associated with CHEK2:p.I157T - findings from the Breast Cancer Association Consortium.

Authors:  Taru A Muranen; Carl Blomqvist; Thilo Dörk; Anna Jakubowska; Päivi Heikkilä; Rainer Fagerholm; Dario Greco; Kristiina Aittomäki; Stig E Bojesen; Mitul Shah; Alison M Dunning; Valerie Rhenius; Per Hall; Kamila Czene; Judith S Brand; Hatef Darabi; Jenny Chang-Claude; Anja Rudolph; Børge G Nordestgaard; Fergus J Couch; Steven N Hart; Jonine Figueroa; Montserrat García-Closas; Peter A Fasching; Matthias W Beckmann; Jingmei Li; Jianjun Liu; Irene L Andrulis; Robert Winqvist; Katri Pylkäs; Arto Mannermaa; Vesa Kataja; Annika Lindblom; Sara Margolin; Jan Lubinski; Natalia Dubrowinskaja; Manjeet K Bolla; Joe Dennis; Kyriaki Michailidou; Qin Wang; Douglas F Easton; Paul D P Pharoah; Marjanka K Schmidt; Heli Nevanlinna
Journal:  Breast Cancer Res       Date:  2016-10-03       Impact factor: 6.466

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.